Russell Investments Group Ltd. raised its stake in Keros Therapeutics, Inc. (NASDAQ:KROS – Get Rating) by 65.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 41,207 shares of the company’s stock after buying an additional 16,348 shares during the quarter. Russell Investments Group Ltd. owned 0.15% of Keros Therapeutics worth $1,979,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also recently added to or reduced their stakes in KROS. Wellington Management Group LLP raised its position in Keros Therapeutics by 1.2% in the 1st quarter. Wellington Management Group LLP now owns 18,984 shares of the company’s stock valued at $1,032,000 after buying an additional 227 shares during the last quarter. California State Teachers Retirement System grew its stake in Keros Therapeutics by 1.9% in the third quarter. California State Teachers Retirement System now owns 19,511 shares of the company’s stock valued at $734,000 after purchasing an additional 364 shares in the last quarter. New York State Common Retirement Fund grew its stake in Keros Therapeutics by 3.9% in the fourth quarter. New York State Common Retirement Fund now owns 13,052 shares of the company’s stock valued at $627,000 after purchasing an additional 493 shares in the last quarter. Tudor Investment Corp Et Al grew its stake in Keros Therapeutics by 5.2% in the third quarter. Tudor Investment Corp Et Al now owns 12,829 shares of the company’s stock valued at $483,000 after purchasing an additional 636 shares in the last quarter. Finally, Almanack Investment Partners LLC. bought a new position in Keros Therapeutics in the third quarter valued at approximately $32,000. Institutional investors and hedge funds own 64.14% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on KROS shares. Cowen started coverage on Keros Therapeutics in a research note on Tuesday, February 14th. They issued an “outperform” rating for the company. Cowen initiated coverage on Keros Therapeutics in a research note on Tuesday, February 14th. They set an “outperform” rating for the company. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research note on Monday, March 6th. Finally, Piper Sandler reduced their price target on Keros Therapeutics from $120.00 to $110.00 in a research note on Friday, May 5th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $103.75.
Keros Therapeutics Stock Up 4.4 %
Keros Therapeutics (NASDAQ:KROS – Get Rating) last released its quarterly earnings results on Thursday, May 4th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($1.14) by ($0.12). During the same quarter in the previous year, the company posted ($1.01) earnings per share. As a group, equities research analysts expect that Keros Therapeutics, Inc. will post -5.44 EPS for the current fiscal year.
About Keros Therapeutics
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis.
- Get a free copy of the StockNews.com research report on Keros Therapeutics (KROS)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.